Skip to main content

ERRATUM article

Front. Neurol., 07 March 2024
Sec. Multiple Sclerosis and Neuroimmunology

Erratum: Delimiting MOGAD as a disease entity using translational imaging

  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Delimiting MOGAD as a disease entity using translational imaging

by Oertel, F. C., Hastermann, M., and Paul, F. (2023). Front. Neurol. 14:1216477. doi: 10.3389/fneur.2023.1216477

Due to a production error, minor text corrections were implemented throughout the article.

A correction has been made to the section “Concluding remarks,” where the question numbers were inadvertently linked to the reference numbers. The section is reproduced below:

“Also, many open questions remain such as: (1) Is the histopathology of the optic nerve and spinal cord comparable between MOG animal models and MOGAD patients (due to the lack of human pathology studies), and which would be the closest to reflect human disease? (2) What causes the gray matter involvement in MOGAD? (3) Is there a relevant portion of MOGAD patients developing a clinically progressive disease course and do we need a disease-specific definition of neuropathological progression? and (4) Should current treatment regimens for MOGAD be reevaluated because (A) no adverse events to, e.g., Fingolimod/Natalizumab (as seen in AQP4-IgG seropositive NMOSD) were observed in MOG-IgG seropositive patients (217) and (B) many treatments have been shown to be beneficial in MOG-induced EAE that are less used in or have been unsuccessful in MS (160, 423–425).”

Due to a production error, the references for “(191, 406) and (408)” were incorrectly written as “Lopez-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol. (2018) 75:1355–63. doi: 10.1001/jamaneurol.2018.1814”, “Talla V, Koilkonda R, Guy J. Gene therapy with single-subunit yeast NADH-ubiquinone oxidoreductase (NDI1) improves the visual function in experimental autoimmune encephalomyelitis (EAE) mice model of multiple sclerosis (MS). Mol Neurobiol. (2020) 57:1952–65. doi: 10.1007/s12035-019-01857-6,” and “Talla V, Koilkonda R. Targeted Kruppel-like factor 4 gene knockout in retinal ganglion cells improves visual function in multiple sclerosis mouse model. eNeuro. (2020) 7:ENEURO.0320-19.2020. doi: 10.1523/ENEURO.0320-19.2020”. These should be “Wendel EM, Thonke HS, Bertolini A, Baumann M, Blaschek A, Merkenschlager A, et al. Temporal dynamics of MOG antibodies in children with acquired demyelinating syndrome. Neurol-Neuroimmunol. (2022) 9:e200035. doi: 10.1212/NXI.0000000000200035”, “Talla V, Porciatti V, Chiodo V, Boye SL, Hauswirth WW, Guy J. Gene therapy with mitochondrial heat shock protein 70 suppresses visual loss and optic atrophy in experimental autoimmune encephalomyelitis. Invest Ophthalmol Vis Sci. (2014) 55:5214–26. doi: 10.1167/iovs.14-14688” and “Talla V, Koilkonda R. Targeted Krüppel-like factor 4 gene knock-out in retinal ganglion cells improves visual function in multiple sclerosis mouse model. eNeuro. (2020) 7:ENEURO.0320-19.2020. doi: 10.1523/ENEURO.0320-19.2020”. Reference 425 and reference 292 were the same and therefore reference 425 was deleted. A total of 11 references (76, 78, 82, 86, 97, 107, 113, 126, 128, 130 and 132) indicated the first published date and not the online issue date.

The publisher apologizes for this mistake. The original article has been updated.

References

191. Wendel EM, Thonke HS, Bertolini A, Baumann M, Blaschek A, Merkenschlager A, et al. Temporal dynamics of MOG antibodies in children with acquired demyelinating syndrome. Neurol-Neuroimmunol. (2022) 9:e200035. doi: 10.1212/NXI.0000000000200035

PubMed Abstract | Crossref Full Text | Google Scholar

406. Talla V, Porciatti V, Chiodo V, Boye SL, Hauswirth WW, Guy J. Gene therapy with mitochondrial heat shock protein 70 suppresses visual loss and optic atrophy in experimental autoimmune encephalomyelitis. Invest Ophthalmol Vis Sci. (2014) 55:5214–26. doi: 10.1167/iovs.14-14688

PubMed Abstract | Crossref Full Text | Google Scholar

408. Talla V, Koilkonda R. Targeted Krüppel-like factor 4 gene knock-out in retinal ganglion cells improves visual function in multiple sclerosis mouse model. eNeuro. (2020) 7:ENEURO.0320-19.2020. doi: 10.1523/ENEURO.0320-19.2020

PubMed Abstract | Crossref Full Text | Google Scholar

Keywords: myelin oligodendrocyte glycoprotein associated disease, imaging, translational research, EAE, animal models

Citation: Frontiers Production Office (2024) Erratum: Delimiting MOGAD as a disease entity using translational imaging. Front. Neurol. 15:1390688. doi: 10.3389/fneur.2024.1390688

Received: 23 February 2024; Accepted: 26 February 2024;
Published: 07 March 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.